Magnitude Biosciences Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.76M
- Investors
-
10
Magnitude Biosciences General Information
Description
Operator of a patented in vivo testing platform designed to accelerate drug and product development through rapid, cost-effective data generation using C. elegans. The company offers high-throughput, whole-organism insights into efficacy, toxicity, and mechanisms of action, enabling pharmaceutical, biotech, and nutraceutical developers to reduce preclinical timelines and costs with an ethical alternative to mammalian models.
Contact Information
Website
www.magnitudebiosciences.comCorporate Office
- NETPark Plexus
- Thomas Wright Way
- Sedgefield TS21 3FD
- England, United Kingdom
Corporate Office
- NETPark Plexus
- Thomas Wright Way
- Sedgefield TS21 3FD
- England, United Kingdom
Magnitude Biosciences Timeline
Magnitude Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 15-Sep-2026 | $1.76M | Completed | Generating Revenue | ||
| 9. Later Stage VC | 30-Mar-2025 | Completed | Generating Revenue | |||
| 8. Grant | 01-Apr-2023 | Completed | Generating Revenue | |||
| 7. Seed Round | 14-Nov-2022 | Completed | Generating Revenue | |||
| 6. Seed Round | 19-Aug-2020 | Completed | Generating Revenue | |||
| 5. Seed Round | 02-Dec-2019 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2019 | Completed | Generating Revenue | |||
| 3. Grant | 01-Oct-2018 | Completed | Startup | |||
| 2. Seed Round | 20-Sep-2018 | $195K | $195K | Completed | Startup | |
| 1. University Spin-Out | 20-Sep-2018 | Completed | Startup |
Magnitude Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Ordinary | ||||||||
| Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 56,400 | $0.001289 | $5.14 | $5.14 | 1x | $5.14 | 13.35% | |
| A Ordinary | 37,600 | $0.001289 | $5.14 | $5.14 | 1x | $5.14 | 8.9% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Magnitude Biosciences Patents
Magnitude Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418752-D0 | Sample holder, and systems and methods for imaging and illuminating samples in a sample holder | Pending | 19-Dec-2024 | ||
| GB-2703759-A | Sample holder, and systems and methods for imaging and illuminating samples in a sample holder | Pending | 19-Dec-2024 | ||
| WO-2026132803-A1 | Sample holder, and systems and methods for imaging and illuminating samples in a sample holder | Pending | 19-Dec-2024 | ||
| GB-2592149-B | Method and apparatus for tracking nematode worms | Active | 18-Oct-2018 | ||
| US-11756214-B2 | Method and apparatus for tracking nematode worms | Active | 18-Oct-2018 | G06T7/254 |
Magnitude Biosciences Signals
Magnitude Biosciences Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| Business Durham | Corporation | Minority | ||
| Maven Capital Partners UK | PE/Buyout | Minority | ||
| Innovate UK | Government | |||
| Government of UK | Government | Minority |
Magnitude Biosciences Acquisitions (1)
Magnitude Biosciences’s most recent deal was a Merger/Acquisition with Invermis. The deal was made on 15-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Invermis | 15-May-2020 | Merger/Acquisition | Biotechnology |
Magnitude Biosciences FAQs
-
When was Magnitude Biosciences founded?
Magnitude Biosciences was founded in 2018.
-
Where is Magnitude Biosciences headquartered?
Magnitude Biosciences is headquartered in Sedgefield, United Kingdom.
-
What is the size of Magnitude Biosciences?
Magnitude Biosciences has 19 total employees.
-
What industry is Magnitude Biosciences in?
Magnitude Biosciences’s primary industry is Drug Discovery.
-
Is Magnitude Biosciences a private or public company?
Magnitude Biosciences is a Private company.
-
What is Magnitude Biosciences’s current revenue?
The current revenue for Magnitude Biosciences is .
-
How much funding has Magnitude Biosciences raised over time?
Magnitude Biosciences has raised $4.61M.
-
Who are Magnitude Biosciences’s investors?
British Business Bank, Business Durham, Maven Capital Partners UK, Innovate UK, and Government of UK are 5 of 10 investors who have invested in Magnitude Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process